[ Pobierz całość w formacie PDF ]
36. Colandene JD, Maldonado LM, Creagh AT, Vrettos JS, Goad thawing. AAPS J 6:e22.
KG, Spitznagel TM. 2007. Lyophilization cycle development for 56. Carlson RH, Garnick RL, Jones AJS, Meunier AM. 1988. The
a high-concentration monoclonal antibody formulation lacking determination of recombinant human tissue-type plasminogen
a crystalline bulking agent. J Pharm Sci 96:1598 1608. activator activity by turbidimetry using a microcentrifugal
37. Lewis LM. 2003. 20040311 Lyophilized formulations of mod- analyzer. Anal Biochem 168:428 435.
ified antibodies, TNFalpha specific humanized antibody 57. Abdul-Fattah AM, Kalonia DS, Pikal MJ. 2007. The challenge
CDP870, and methods of making the same. 2003-US24413: of drying method selection for protein pharmaceuticals: Pro-
34. duct quality implications. J Pharm Sci 96:1886 1916.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 5, MAY 2010 DOI 10.1002/jps
EFFECT OF LYOPHILIZATE COLLAPSE 2277
58. Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2003. tions: Correlation with static and dynamic light scattering
Effects of annealing lyophilized and spray-lyophilized formula- measurements. Biophys J 92:234 244.
tions of recombinant human interferon-gamma. J Pharm Sci 76. Hernandez-Contreras M, arcon-Waess O, Medina-Noyola M.
92:715 729. 1997. Rotational-translational electrolyte friction on nonsphe-
59. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. rical particles. J Chem Phys 106:2492 2501.
Effect of moisture on the stability of a lyophilized humanized 77. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein
monoclonal antibody formulation. Pharm Res 18:1345 1353. pharmaceuticals. Pharm Res 6:903 918.
60. Duddu SP, Dal Monte PR. 1997. Effect of glass transition 78. Byler DM, Susi H. 1986. Examination of the secondary struc-
temperature on the stability of lyophilized formulations con- ture of proteins by deconvolved FTIR spectra. Biopolymers
taining a chimeric therapeutic monoclonal antibody. Pharm 25:469 487.
Res 14:591 595. 79. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Chamow
61. Hatley RHM. 1997. Glass fragility and the stability of phar- SM. 2003. Influence of histidine on the stability and physical
maceutical preparations-excipient selection. Pharm Dev Tech- properties of a fully human antibody in aqueous and solid
nol 2:257 264. forms. Pharm Res 20:1952 1960.
62. Angell CA. 1995. Formation of glasses from liquids and biopo- 80. Fu FN, DeOliveira DB, Trumble WR, Sarkar HK, Singh BR.
lymers. Science (Washington, DC) 267: 1924 1935. 1994. Secondary structure estimation of proteins using the
63. Yu L, Milton N, Groleau EG, Mishra DS, Vansickle RE. 1999. amide III region of Fourier transform infrared spectroscopy:
Existence of a mannitol hydrate during freeze-drying and Application to analyze calcium-binding-induced structural
practical implications. J Pharm Sci 88:196 198. changes in calsequestrin. Appl Spectrosc 48: 1432 1441.
64. Cavatur RK, Suryanarayanan R. 1998. Characterization of 81. Levitt M, Greer J. 1977. Automatic identification of secondary
phase transitions during freeze-drying by in situ X-ray powder structure in globular proteins. J Mol Biol 114:181 239.
diffractometry. Pharm Dev Technol 3:579 586. 82. Costantino HR, Andya JD, Shire SJ, Hsu CC. 1997. Fourier-
65. Gombas A, Szabo-Revesz P, Regdon G, Jr., Eroes I. 2003. Study transform infrared spectroscopic analysis of the secondary
of thermal behaviour of sugar alcohols. J Therm Anal Calorim structure of recombinant humanized immunoglobulin G.
73:615 621. Pharm Sci 3:121 128.
66. Hawe A, Friess W. 2006. Physico-chemical lyophilization beha- 83. Dong A, Prestrelski SJ, Allison SD, Carpenter JF. 1995. Infra-
vior of mannitol, human serum albumin formulations. Eur J red spectroscopic studies of lyophilization- and temperature-
Pharm Sci 28:224 232. induced protein aggregation. J Pharm Sci 84:415 424.
67. Hawe A. 2006. Studies on Stable Formulations for a Hydro- 84. Prestrelski S, Tedeschi N, Arakawa T, Carpenter JF. 1993.
phobic Cytokine. (Dissertation Ludwig-Maximilians-Universi- Dehydration-induced conformational transitions in proteins
tät München). and their inhibition by stabilizers. Biophys J 65:661 671.
68. Izutsu Ki, Yoshioka S, Kojima S. 1995. Increased stabilizing 85. Prestrelski SJ, Arakawa T, Carpenter JF. 1994. Structure of
effects of amphiphilic excipients on freeze-drying of lactate proteins in lyophilized formulations using Fourier transform
dehydrogenase (LDH) by dispersion into sugar matrixes. infrared spectroscopy. ACS Symp Ser 567:148 169.
Pharm Res 12: 838 843. 86. Carpenter JF, Prestrelski SJ, Dong A. 1998. Application of
69. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, infrared spectroscopy to development of stable lyophilized pro-
Carpenter JF, Randolph TW. 2006. Quantitation of aggregate tein formulations. Eur J Pharm Biopharm 45:231 238.
levels in a recombinant humanized monoclonal antibody for- 87. Izutsu K, Yoshioka S, Takeda Y. 1991. The effects of additives
mulation by size-exclusion chromatography, asymmetrical flow on the stability of freeze-dried b-galactosidase stored at ele-
field flow fractionation, and sedimentation velocity. J Pharm vated temperature. Int J Pharm 71:137 146.
Sci 96:268 279. 88. Prestrelski SJ, Pikal KA, Arakawa T. 1995. Optimization of
70. Litzen A, Walter JK, Krischollek H, Wahlund KG. 1993. lyophilization conditions for recombinant human interleukin-2
Separation and quantitation of monoclonal antibody aggre- by dried-state conformational analysis using Fourier-trans-
gates by asymmetrical flow field-flow fractionation and com- form infrared spectroscopy. Pharm Res 12:1250 1259.
parison to gel permeation chromatography. Anal Biochem 89. Tian F, Middaugh CR, Offerdahl T, Munson E, Sane S, Rytting
212:469 480. JH. 2007. Spectroscopic evaluation of the stabilization of huma-
[ Pobierz całość w formacie PDF ]